Therapeutic potential of HMGB1-targeting agents in sepsis

Expert Reviews in Molecular Medicine

Volumn 10, Issue 32, 2008, Pages 1-20

  Wang, Haichao ^a   Zhu, Shu ^a,b   Zhou, Rongrong ^a,c   Li, Wei ^a,b   Sama, Andrew E ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBIN III; AUTACOID; DANAPAROID; DEXAMETHASONE; DNA BINDING PROTEIN; DROTRECOGIN; FLUDROCORTISONE; GHRELIN; HEPARIN; HERBACEOUS AGENT; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; IMMUNOGLOBULIN; INSULIN; METHYLPREDNISOLONE; NEUROPEPTIDE; NEUTRALIZING ANTIBODY; NORADRENALIN; PLACEBO; RECOMBINANT THROMBOMODULIN; STEROID; TANSHINONE; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASOPRESSIN;

APOPTOSIS; ARTICLE; BACTEREMIA; CELL ACTIVATION; CELL MIGRATION; CELL STIMULATION; CLINICAL TRIAL; DISEASE MODEL; DISEASE SEVERITY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; ENDOTOXEMIA; EXPERIMENTAL INFECTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; INFECTION; INNATE IMMUNITY; INSULIN TREATMENT; ISCHEMIA; LOW DRUG DOSE; MACROPHAGE; MONOCYTE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RESUSCITATION; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE INJURY; VAGUS NERVE STIMULATION;

ANIMALIA;

EID: 56049128160     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399408000884     Document Type: Article

References (152)

1. Serhan, C.N. and Savill, J. (2005) Resolution of inflammation: The beginning programs the end. Nat Immunol 6, 1191-1197
2. Dellinger, R.P. et al. (2008) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36, 296-327
3. Luster, A.D., Alon, R., and von Andrian, U.H. (2005) Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol 6, 1182-1190
4. Scapini, P. et al. (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177, 195-203
5. Liles, W.C. (2001) Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect 16, 11-17
6. Mosser, D.M. (1999) Receptors on phagocytic cells involved in microbial recognition. Immunol Ser 60, 99-114
7. Wu, Y, Tibrewal, N. and Birge, R.B. (2006) Phosphatidylserine recognition by phagocytes: A view to a kill. Trends Cell Biol 16, 189-197
8. Hemmi, H. et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745
9. Krieg, A.M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20, 709-760
10. Brightbill, H.D. et al. (1999) Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285, 732-736
11. Poltorak, A. et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: Mutations in Tlr4 gene. Science 282, 2085-2088
12. Akira, S. and Takeda, K. (2004) Toll-like receptor signalling. Nat Rev Immunol 4, 499-511
13. Baggiolini, M. and Loetscher, P. (2000) Chemokines in inflammation and immunity. Immunol Today 21, 418-420
14. Balkwill, F. (1988) Cytokines-soluble factors in immune responses. Curr Opin Immunol 1, 241-249
15. Wichterman, K.A., Baue, A.E. and Chaudry, I.H. (1980) Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 29, 189-201
16. Lowenstein, C.J., Dinerman, J.L. and Snyder, S.H. (1994) Nitric oxide: A physiologic messenger. Ann Intern Med 120, 227-237
17. Tracey, K.J. et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664
18. Dinarello, C.A. andThompson, R.C. (1991) Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12, 404-410
19. Block, M.I. et al. (1993) Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia. J Exp Med 178, 1085-1090
20. Heinzel, F.P. (1990) The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol 145, 2920-2924
21. Bernhagen, J. et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756-759
22. Calandra, T. et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6, 164-170
23. Bozza, M. et al. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189, 341-346
24. Davis, C.E. et al. (1969) Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin. J Immunol 102, 563-572
25. Knudsen, P.J. et al. (1986) Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 137, 3189-3194
26. Oswald, I.P. et al. (1992) Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci U S A 89, 8676-8680
27. Bogdan, C., Vodovotz, Y. and Nathan, C. (1991) Macrophage deactivation by interleukin 10. J Exp Med 174, 1549-1555
28. Tsunawaki, S. et al. (1988) Deactivation of macrophages by transforming growth factor-beta. Nature 334, 260-262
29. Miller-Graziano, C.L. et al. (1991) Role of elevated monocyte transforming growth factor beta (TGF beta) production in posttrauma immunosuppression. J Clin Immunol 11, 95-102
30. Zhang, M. et al. (1997) Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: A counterregulatory mechanism that restrains the immune response. J Exp Med 185, 1759-1768
31. Zhang, M. et al. (1999) Spermine inhibition of monocyte activation and inflammation. Mol Med 5, 595-605
32. Wang, H. et al. (1998) Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci U S A 95, 14429-14434
33. Zhang, M., Wang, H. and Tracey, K.J. (2000) Regulation of macrophage activation and inflammation by spermine: A new chapter in an old story. Crit Care Med 28, N60-N66
34. Borovikova, L.V. et al. (2000) Vagus nervestimulation attenuates the systemic inflammatory response to endotoxin. Nature 405, 458-462
35. Lefering, R. and Neugebauer, E.A. (1995) Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 23, 1294-1303
36. Annane, D. et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288, 862-871
37. Sprung, C.L. et al. (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358, 111-124
38. Bernard, G.R. et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344, 699-709
39. Warren, B.L. et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 286, 1869-1878
40. Abraham, E. et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 290, 238-247
41. Rivers, E. et al. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345, 1368-1377
42. Sama, A.E. et al. (2004) Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department. Acad Emerg Med 11, 867-873
43. Russell, J.A. et al. (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358, 877-887
44. van den Berghe, G. et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345, 1359-1367
45. van den Berghe, G. et al. (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354, 449-461
46. Brunkhorst, F.M. et al. (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358, 125-139
47. Chen, G. et al. (2005) Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:aN additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46, 623-627
48. Bonaldi, T. et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22, 5551-5560
49. Bustin, M. (2002) At the crossroads of necrosis and apoptosis: Signaling to multiple cellular targets by HMGB1. Sci STKE 2002, E39
50. Oppenheim, J.H. and Yang, D. (2005) Alarmins: Chemotactic activators of immune responses. Curr Opin Immunol 17, 359-365
51. Wang, H. et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251
52. Ivanov, S. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110, 1970-1981
53. Rendon-Mitchell, B. et al. (2003) IFN-gamma Induces High Mobility Group Box 1 Protein Release Partly Through a TNF-Dependent Mechanism. J Immunol 170, 3890-3897
54. Tang, D. et al. (2007) Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81, 741-747
55. Gardella, S. et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3, 955-1001
56. Scaffidi, P., Misteli, T. and Bianchi, M.E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195
57. Chu, J.J. and Ng, M.L. (2003) The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J Gen Virol 84, 3305-3314
58. Joseph, T. et al. (2004) Mechanism of cell death during infectious salmon anemia virus infection is cell type-specific. J Gen Virol 85, 3027-3036
59. Chen, L.C. et al. (2008) Dengue virus infection induces passive release of high mobility group box 1 protein by epithelial cells. J Infect 56, 143-150
60. Wang, H. et al. (2006) Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 19, 3-9
61. Fages, C. et al. (2000) Regulation of cell migration by amphoterin. J Cell Sci 113 (Pt 4), 611-620
62. Degryse, B. et al. (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152, 1197-1206
63. Huttunen, H.J. et al. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62, 4805-4811
64. Palumbo, R. et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164, 441-449
65. Palumbo, R. et al. (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179, 33-40
66. Rouhiainen, A. et al.(2004) Regulation of monocyte migration by amphoterin (HMGB1). Blood 104, 1174-1182
67. Yang, D. et al. (2007) High mobility group box-1 protein induces the migration and activation of human dendritic cells andacts as an alarmin. J Leukoc Biol 81, 59-66
68. Dumitriu, I.E. et al. (2007) The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81, 84-91
69. Orlova, V.V. et al. (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment hat requires Mac-1-integrin. EMBO J 26, 1129-1139
70. Degryse, B. and de Virgilio, M. (2003) The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett 553, 11-17
71. Tian, J. et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8, 487-496
72. Silva, E. et al. (2007) HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Med 33, 1829-1839
73. Park, J.S. et al. (2004) Involvement of TLR 2 and TLR 4 in cellular activation by high mobility group box 1 protein (HMGB1). J Biol Chem 279, 7370-7377
74. Yu, M. et al. (2006) HMGB1 signals through Toll-like Receptor (TLR) 4 and TLR2. Shock 26, 174-179
75. Park, J.S. et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290, C917-C924
76. Kokkola, R. et al. (2005) RAGE is the Major Receptor for the Proinflarnmatory Activity of HMGB1 in Rodent Macrophages. Scand J Immunol 61, 1-9
77. Pedrazzi, M. et al. (2007) Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol 179, 8525-8532
78. Fiuza, C. et al. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652-2660
79. Treutiger, C.J. et al. (2003) High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 254, 375-385
80. Yang, H. et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101, 296-301
81. Kokkola, R. et al. (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48, 2052-2058
82. Li, J. et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9, 37-45
83. Messmer, D. et al. (2004) High mobility group box protein 1: An endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173, 307-313
84. Li, W. et al. (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS ONE 2, e1153
85. Andersson, U. et al. (2000) High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes. J Exp Med 192, 565-570
86. Agnello, D. et al. (2002) HMGB1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine 18, 231-236
87. Pedrazzi, M. et al. (2006) Stimulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein. J. Neurochem 99, 827-838
88. O'Connor, K.A. et al. (2003) Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: Central nervous system effects. Cytokine 24, 254-265
89. Liu, K. et al. (2007) Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21, 3904-3916
90. Abraham, E. et al. (2000) HMG-1 as a mediator of acute lung inflammation. J Immunol 165, 2950-2954
91. Ueno, H. et al. (2004) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170, 1310-1316
92. Lin, X. et al. (2005) (alpha)-Chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol 289, L583-L590
93. Liu, G. et al. (2008) High mobility group protein-1 Inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 181, 4240-4246
94. Bell, C.W. et al. (2006) The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291, C1318-1325
95. Qin, S. et al. (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203, 1637-1642
96. Wang, H. et al. (2001) HMGB1 as a Late Mediator of Lethal Systemic Inflammation. Am J Respir Crit Care Med 164, 1768-1773
97. Suda, K. et al. (2006) Anti-high-mobility group box chromosomalprotein 1 antibodies improve survival of rats with sepsis. World J Surg 30, 1755-1762
98. Sappington, P.L. et al. (2002) HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123, 790-802
99. Tsung, A. et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201, 1135-1143
100. Oozawa, A. et al. (2008) Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 72, 1178-1184
101. Wu, H. et al. (2007) TLR4 activation mediates kidney ischemia/ reperfusion injury. J Clin Invest 117, 2847-2859
102. Liu, K. et al. (2007) Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21, 3904-3916
103. Andrassy, M. et al. (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117, 3216-3226
104. Ogawa, E.N. et al. (2006) Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med 174, 400-407
105. Sawa, H. et al. (2006) Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol 12, 7666-7670
106. Yang, R. et al. (2006) Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 12, 105-114
107. Li, W., Sama, A.E. and Wang, H. (2006) Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol 6, 130-135
108. Czermak, B.J. et al. (1999) Protective effects of C5a blockade in sepsis. Nat Med 5, 788-792
109. Riedemann, N.C. et al. (2002) Increased C5a receptor expression in sepsis. J Clin Invest 110, 101-108
110. Rittirsch, D. et al. (2008) Functional roles for C5a receptors in sepsis. Nat Med 14, 551-557
111. Hagiwara, S. et al. (2008) High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 34, 361-367
112. Abeyama, K. (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115, 1267-1274
113. Hagiwara, S. et al. (2008) Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Crit Care 12, R43
114. Hagiwara, S. et al. (2008) High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis. Intensive Care Med 34, 1812-1819
115. Urbonaviciute, V. et al. (2007) Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 81, 67-74
116. Hagiwara, S. et al. (2008) Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 36, 2407-2413
117. Wang, H. et al. (2008) Hyperglycemia aggravates endotoxin-induced high mobility group box 1 protein release: Yet another reason not to be too sweet. Crit Care Med 36, 2475-2476
118. Chorny, A. and Delgado, M. (2008) Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 172, 1297-1307
119. Tang, Y. et al. (2008) PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol 8, 1646-1651
120. Wu, R. et al. (2007) Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med 176, 805-813
121. Wu, R. et al. (2007) Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg 245, 480-486
122. Chorny, A. et al. (2008) Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 180, 8369-8377
123. Tracey, K.J. (2007) Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 117, 289-296
124. Wang, H. et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421, 384-388
125. Huston, J.M. et al. (2006) Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 203, 1623-1628
126. Huston, J.M. et al. (2007) Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 35, 2762-2768
127. Wang, H. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10, 1216-1221
128. Pavlov, V.A. et al. (2007) Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 35, 1139-1144
129. Yan, J.J. et al. (2004) Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10, 161-167
130. Wang, H., Czura, C.J. and Tracey, K.J. (2004) Lipid unites disparate syndromes of sepsis. Nat Med 10, 124-125
131. Fink, M.P. (2007) Ethyl pyruvate: A novel treatment for sepsis. Curr Drug Targets 8, 515-518
132. Ulloa, L. et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 99, 12351-12356
133. Zhu, S. et al. (2008) Caging a beast in the inflammation arena: Use of Chinese medicinal herbs to inhibit a late mediator of lethal sepsis, HMGB1. Int J Clin Exp Med 1, 64-79
134. Wang, H. et al. (2006) The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 136, 360-365
135. Li, W. et al. (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 178, 3856-3864
136. Piersen, C.E. (2003) Phytoestrogens in botanical dietary supplements: implications for cancer. Integr Cancer Ther 2, 120-138
137. Osuchowski,M.F. et al. (2006)Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177, 1967-1974
138. Ji, X.Y., Tan, B.K. and Zhu, Y.Z. (2000) Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 21, 1089-1094
139. Cheng, T.O. (2007) Cardiovascular effects of Danshen. Int J Cardiol 121, 9-22
140. Beutler, B., Milsark, I.W. and Cerami, A.C. (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869-871
141. Ziegler, E.J. et al. (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324, 429-436
142. Ziegler, E.J. et al. (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307, 1225-1230
143. Abraham, E. et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273, 934-941
144. Cohen, J. (1999) Adjunctive therapy in sepsis: A critical analysis of the clinical trial programme. Br Med Bull 55, 212-225
145. Feldmann, M. and Maini, R.N. (2001) Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 19, 163-196
146. Wang, H., Yang, H. and Tracey, K.J. (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255, 320-331
147. Lotze, M.T. and Tracey, K.J. (2005) High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342
148. Sunden-Cullberg, J. et al. (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33, 564-573
149. Angus, D.C. et al. (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35, 1061-1067
150. Sha, Y. et al. (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180, 2531-2537
151. Kazama, H. et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29, 21-32
152. Tzeng, H.P. et al. (2008) Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol 294, H1490-H1496 antiserum to a mutant Escherichia coli. N Engl J Med 307, 1225-1230